TY - JOUR
T1 - The evolving treatment landscape of advanced urothelial carcinoma
AU - Andreev-Drakhlin, Alexander Y.
AU - Egoryan, Goar
AU - Shah, Amishi Y.
AU - Msaouel, Pavlos
AU - Alhalabi, Omar
AU - Gao, Jianjun
N1 - Publisher Copyright:
© 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - Purpose of reviewBladder cancer is the 10th most common cancer in the world and the 6th most common cancer among men. In the past few years, several new agents have been approved for the treatment of urothelial tumors. In this paper, we review the evolving treatment landscape of advanced urothelial carcinoma (UC).Recent findingsSince 2016, the Food and Drug Administration (FDA) has approved five immunotherapies targeting programmed cell death 1/programmed cell death 1 legend, an antinectin-4 antibody drug conjugate (ADC), and a fibroblast growth factor receptor (FGFR) inhibitor for the treatment of patients with advanced UC. Moreover, there are multiple targeted agents, immune checkpoint inhibitors (ICI), ADCs, and their combinations currently being tested in clinical studies with the goal of obtaining FDA approval.SummaryPrecision oncology efforts continue to advance our understanding of the UC biology and transform the existing treatment paradigms. An enlarging arsenal of treatment options promises further personalization of UC therapy.
AB - Purpose of reviewBladder cancer is the 10th most common cancer in the world and the 6th most common cancer among men. In the past few years, several new agents have been approved for the treatment of urothelial tumors. In this paper, we review the evolving treatment landscape of advanced urothelial carcinoma (UC).Recent findingsSince 2016, the Food and Drug Administration (FDA) has approved five immunotherapies targeting programmed cell death 1/programmed cell death 1 legend, an antinectin-4 antibody drug conjugate (ADC), and a fibroblast growth factor receptor (FGFR) inhibitor for the treatment of patients with advanced UC. Moreover, there are multiple targeted agents, immune checkpoint inhibitors (ICI), ADCs, and their combinations currently being tested in clinical studies with the goal of obtaining FDA approval.SummaryPrecision oncology efforts continue to advance our understanding of the UC biology and transform the existing treatment paradigms. An enlarging arsenal of treatment options promises further personalization of UC therapy.
UR - http://www.scopus.com/inward/record.url?scp=85103993651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103993651&partnerID=8YFLogxK
U2 - 10.1097/CCO.0000000000000722
DO - 10.1097/CCO.0000000000000722
M3 - Review article
C2 - 33818541
AN - SCOPUS:85103993651
SN - 1040-8746
VL - 33
SP - 221
EP - 230
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 3
ER -